PWAR5 and thyroid cancer: Finally, we reported that PAR5 directly interacts with EZH2 in thyroid cancer cells, reducing its binding on the E-cadherin promoter, then relieving E-cadherin from the negative control by EZH2 in PAR5-overexpressing ATC cell lines.